Sun PeiJie, Yang Jinfeng, Li Na, Yang Weicheng, Yang Jinqi, Ran Jianxin, Cheng Fang, Liao Yuanpeng
Department of Sports Medicine and Health, Chengdu Sport University, Chengdu, Sichuan, China.
Institute of Sports Medicine and Health, Chengdu Sport University, Chengdu, Sichuan, China.
BMJ Open. 2025 Jan 15;15(1):e085474. doi: 10.1136/bmjopen-2024-085474.
Sarcopenia is a condition that occurs more frequently in older adults. Although many types of exercise have been used in the treatment of sarcopenia, few studies have been conducted on different interventional environments for sarcopenia. The purpose of this study is to investigate the effects of aquatic exercise and land-based exercise on the body composition and function of participants with sarcopenia.
This randomised, controlled, single-blinded trial will enrol 45 participants (≥ 65 years) following the diagnostic criteria set by the Asian Working Group for Sarcopenia 2019. Participants will be randomised and assigned to one of three groups (aquatic exercise group, land-based exercise group and control group). Assessments will be conducted four times: initially (before intervention), after 8 weeks (intermediate), after 16 weeks (final) and 16 weeks after the end of intervention (follow-up). The primary outcomes are appendicular skeletal muscle index and handgrip strength, while the secondary outcomes include the Short Physical Performance Battery, 6-minute walk test and the Chinese version of the 36-item short-form of health-related quality of life.
Ethics approval was obtained from the Ethics Committee of Chengdu Sport University, with permission number CDSUEC2023-125. This study has been registered with the Chinese Clinical Trial Registry (ChiCTR2300077457). All participants will provide written informed consent.
Chinese Clinical Trial Registry ChiCTR2300077457.
肌肉减少症在老年人中更为常见。尽管许多类型的运动已被用于治疗肌肉减少症，但针对肌肉减少症不同干预环境的研究却很少。本研究的目的是调查水上运动和陆地运动对肌肉减少症参与者身体成分和功能的影响。
本随机、对照、单盲试验将按照2019年亚洲肌肉减少症工作组制定的诊断标准招募45名参与者（≥65岁）。参与者将被随机分配到三组之一（水上运动组、陆地运动组和对照组）。评估将进行四次：最初（干预前）、8周后（中期）、16周后（末期）以及干预结束后16周（随访）。主要结局指标是四肢骨骼肌指数和握力，次要结局指标包括简短体能测试、6分钟步行试验以及中文版36项简短健康相关生活质量量表。
已获得成都体育大学伦理委员会的伦理批准，批准号为CDSUEC2023 - 125。本研究已在中国临床试验注册中心注册（注册号：ChiCTR2300077457）。所有参与者将提供书面知情同意书。
中国临床试验注册中心ChiCTR2300077457
